[{"orgOrder":0,"company":"Roskamp Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nilvadipine","moa":"Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Roskamp Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Roskamp Institute \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Roskamp Institute \/ Undisclosed"},{"orgOrder":0,"company":"Prof Brian Lawlor","sponsor":"University of Dublin, Trinity College | Molecular Medicine Ireland LBG | Alzheimer Europe | Archer Pharmaceuticals, Inc. | E-Search Limited | University College Dublin | King's College London | Istituto Mario Negri | University Hospital, Lille | Universit","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nilvadipine","moa":"Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Prof Brian Lawlor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prof Brian Lawlor \/ University of Dublin, Trinity College | Molecular Medicine Ireland LBG | Alzheimer Europe | Archer Pharmaceuticals, Inc. | E-Search Limited | University College Dublin | King's College London | Istituto Mario Negri | University Hospital, Lille | Universit","highestDevelopmentStatusID":"10","companyTruncated":"Prof Brian Lawlor \/ University of Dublin, Trinity College | Molecular Medicine Ireland LBG | Alzheimer Europe | Archer Pharmaceuticals, Inc. | E-Search Limited | University College Dublin | King's College London | Istituto Mario Negri | University Hospital, Lille | Universit"}]

Find Clinical Drug Pipeline Developments & Deals for Nilvadipine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Roskamp Institute

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Roskamp Institute

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : The data from the trial showed that early-stage Alzheimer’s patients who were taking Nilvadipine showed less cognitive decline over an 18-month period than patients treated with placebo.

                          Product Name : Nilvadil

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 06, 2020

                          Lead Product(s) : Nilvadipine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Prof Brian Lawlor

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Prof Brian Lawlor

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Lead Product(s) : Nilvadipine

                          Therapeutic Area : Neurology

                          Study Phase : Phase III

                          Sponsor : University of Dublin, Trinity College | Molecular Medicine Ireland LBG | Alzheimer Europe | Archer Pharmaceuticals, Inc. | E-Search Limited | University College Dublin | King's College London | Istituto Mario Negri | University Hospital, Lille | Universit

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Nilvadipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alzheimer Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 20, 2013

                          Lead Product(s) : Nilvadipine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : University of Dublin, Trinity College | Molecular Medicine Ireland LBG | Alzheimer Europe | Archer Pharmaceuticals, Inc. | E-Search Limited | University College Dublin | King's College London | Istituto Mario Negri | University Hospital, Lille | Universit

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank